References
- The National Institute of Diabetes and Digestive and Kidney Disease. Division of Kidney, Urologic, and Hematologic Diseases. US Renal Data Systems. USRDS 2006 Annual Data Report: Atlas of End Stage Renal Diseases in the United States. Bethesda, MD, USA: National Institutes of Health, 2006
- Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? Special report from the National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidn Dis 1998;32:853-906
- Pascual JM, Rodilla E, Costa JA, et al. Prognostic value of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2014;64:1228-34
- Meccariello A, Buono F, Verrengia E, et al. Microalbuminuria predicts the recurrence of cardiovascular events in patients with essential hypertension. J Hypertens 2016;34:646-53
- Mancia G, Fagard R, Narkiewicz K, et al.; Task Force Members. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-357
- Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13-18
- Perry HM Jr, Miller JP, Fornoff JR, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995;25:587-94
- Rosansky SJ, Hoover DR, King L, et al. The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Arch Intern Med 1990;150:2073-6
- Khosla N, Bakris G. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol 2006;1:229-35
- Duka I, Bakris G. Influence of microalbuminuria in achieving blood pressure goals. Curr Opin Nephrol Hypertens 2008;17:457-63
- Robles NR, Velasco J, Espinosa J, et al.; on behalf of the MICREX Group Investigators. Persistent microalbuminuria after treatment with renin–angiotensin axis blockers; causes and results of treatment intensification. J Renin Angiotensin Aldosterone Syst 2011;12:333-9
- Burnier M. Renal protection with calcium antagonists: the role of lercanidipine. Curr Med Res Opin 2013;29:1727-35
- National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999;34:1129-33
- Voyaki SM, Staessen JA, Thijs L, et al. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. J Hypertens 2001;19:511-19
- Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72
- Mancia G, Brown M, Castaigne A, et al.; INSIGHT. Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003;41:431-6
- Sabbatini M, Leonardi A, Testa R, et al. Effects of dihydropyridine-type Ca2+ antagonists on the renal arterial tree in spontaneously hypertensive rats. J Cardiovasc Pharmacol 2002;39:39-48
- Dalla Vestra M, Pozza G, Mosca A, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type II diabetic patients with microalbuminuria: DIAL Study (diabete, ipertensione, albuminuria, lercanidipina). Diab Nutr Metab 2004;17:259-66
- Robles NR, Ocon J, Gomez Campderá F, et al. Lercanidipine in chronic renal failure patients: the ZAFRA study. Renal Fail 2005;27:73-80
- Robles NR, Romero B, de Vinuesa EG, et al. Treatment of proteinuria with lercanidipine associated with renin–angiotensin axis-blocking drugs. Ren Fail 2010;32:192-7
- Hayashi K, Homma K, Wakino S, et al. T-type Ca channel blockade as a determinant of kidney protection. Keio J Med 2010;59:84-95